

Clinical Policy: Buprenorphine Injection (Sublocade, Brixadi)

Reference Number: CP.PHAR.289

Effective Date: 12.01.16

Last Review Date: 02.24

Line of Business: Commercial, HIM, Medicaid

[Coding Implications](#)

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

Description

Buprenorphine (Sublocade[®], Brixadi[®]) is a partial opioid agonist.

FDA Approved Indication(s)

Sublocade is indicated for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a buprenorphine-containing product, followed by dose adjustment for a minimum of 7 days.

Brixadi is indicated for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a single dose of transmucosal buprenorphine product or who are already being treated with buprenorphine.

Sublocade and Brixadi should be used as part of a complete treatment program that includes counseling and psychosocial support.

Sublocade and Brixadi are administered only by healthcare providers in a healthcare setting

Policy/Criteria

Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation[®] that Sublocade and Brixadi are **medically necessary** when the following criteria are met:

I. Initial Approval Criteria*

*For members in Nevada, medical management techniques, including quantity management, beyond step therapy is not allowed.

A. Opioid Dependence (must meet all):

1. Diagnosis of opioid dependence;
2. Age \geq 18 years;
3. Member meets one of the following (a, b, or c):
 - a. Member is switching from another non-transmucosal buprenorphine-containing product (e.g., Sublocade, Brixadi);
 - b. For Sublocade requests, member is currently on a transmucosal buprenorphine-containing product, delivering the equivalent of 8 mg to 24 mg of buprenorphine daily, for 7 days or longer;

- c. For Brixadi requests, member meets one of the following (i or ii):
 - i. Has tolerated a single 4 mg dose of transmucosal buprenorphine-containing product;
 - ii. Currently is being treated with a transmucosal buprenorphine-containing product;
4. Medical justification supports inability to continue to use transmucosal (e.g., sublingual, buccal) formulations of buprenorphine as evidenced by one of the following (a, b, c, or d):
 - a. Documentation of non-compliance to transmucosal formulations of buprenorphine;
 - b. Treatment failure with transmucosal formulations of buprenorphine;
 - c. History of diversion with buprenorphine medication-assisted treatment (MAT) products;
 - d. Contraindication(s) or clinically significant adverse effects to the excipients of transmucosal formulations of buprenorphine;
5. Dose does not exceed any of the following (a or b):
 - a. Sublocade: 300 mg per month;
 - b. Brixadi (i or ii):
 - i. 32 mg per week;
 - ii. 128 mg every 28 days.

Approval duration:

Medicaid/Commercial – 6 months (*12 months for New Hampshire*)

HIM – 12 months

B. Other diagnoses/indications (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
 - a. For drugs on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.33 for health insurance marketplace, and CP.PMN.255 for Medicaid; or
 - b. For drugs NOT on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.103 for health insurance marketplace, and CP.PMN.16 for Medicaid; or
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid.

II. Continued Therapy*

*For members in Nevada, medical management techniques, including quantity management, beyond step therapy is not allowed.

A. Opioid Dependence (must meet all):

1. Member meets one of the following (a or b):

- a. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
- b. Member is currently receiving medication and is enrolled in a state and product with continuity of care regulations (*refer to state specific addendums for CC.PHARM.03A and CC.PHARM.03B*);
2. Member is responding positively to therapy;
3. One of the following conditions is met (a or b):
 - a. Member has NOT received an opioid analgesic since last approval;
 - b. Prescriber submits documentation acknowledging that the use of opioid during the last approval period was due to a diagnosis of acute pain;
4. If request is for a dose increase, new dose does not exceed any of the following (a or b):
 - a. Sublocade: 300 mg per month;
 - b. Brixadi (i or ii):
 - i. 32 mg per week;
 - ii. 128 mg every 28 days.

Approval duration:

Medicaid/Commercial – 6 months (*12 months for New Hampshire*)

HIM – 12 months

B. Other diagnoses/indications (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
 - a. For drugs on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.33 for health insurance marketplace, and CP.PMN.255 for Medicaid; or
 - b. For drugs NOT on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.103 for health insurance marketplace, and CP.PMN.16 for Medicaid; or
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid.

III. Diagnoses/Indications for which coverage is NOT authorized:

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid, or evidence of coverage documents.

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

FDA: Food and Drug Administration

MAT: medication-assisted treatment

REMS: Risk Evaluation and Mitigation Strategy

SL: sublingual

Appendix B: Therapeutic Alternatives

This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.

| Drug Name | Dosing Regimen | Dose Limit/ Maximum Dose |
|---|---|-----------------------------|
| buprenorphine (Subutex) sublingual (SL) tablet | <u>Maintenance</u> : Target dose: 16 mg PO once daily; dosage should be adjusted in increments or decrements of 2 mg or 4 mg to a level that maintains treatment and suppresses opioid withdrawal symptoms; usual range: 4 mg to 24 mg per day | 24 mg per day |
| buprenorphine/naloxone (Suboxone) SL or buccal dissolving film, SL tablet | <u>Maintenance</u> : Target dose: buprenorphine 16 mg/naloxone 4 mg PO once daily; dosage should be adjusted in increments or decrements of 2 mg/0.5 mg or 4 mg/1 mg to a level that maintains treatment and suppresses opioid withdrawal symptoms; usual range: 4 mg/1 mg to 24 mg/6 mg per day | 24 mg/6 mg per day |
| Bunavail [®] (buprenorphine/naloxone) buccal film | <u>Maintenance</u> : Target dose: buprenorphine 8.4 mg/naloxone 1.4 mg PO once daily; dosage should be adjusted in increments or decrements of 2.1 mg/0.3 mg to a level that maintains treatment and suppresses opioid withdrawal symptoms; usual range: 2.1 mg/0.3 mg to 12.6 mg/2.1 mg per day | 12.6 mg/2.1 mg per day |
| Zubsolv [®] (buprenorphine/naloxone) SL tablet | <u>Maintenance</u> : Target dose: buprenorphine 11.4 mg/naloxone 2.9 mg PO once daily; dosage should be adjusted in increments or decrements of 2.9 mg/0.71 mg to a level that maintains treatment and suppresses opioid withdrawal symptoms; usual range: 2.9 mg/0.71 mg to 17.2 mg/4.2 mg per day | 17.2 mg/4.2 mg per day |

Therapeutic alternatives are listed as Brand name[®] (generic) when the drug is available by brand name only and generic (Brand name[®]) when the drug is available by both brand and generic.

Appendix C: Contraindications/Boxed Warnings

- Contraindication(s): hypersensitivity to buprenorphine or any other ingredients in Sublocade or Brixadi

- Boxed warning(s): risk of serious harm or death with intravenous administration; available only through a restricted program called the Sublocade or Brixadi REMS Program

Appendix D: Brand/Generic Transmucosal Formulations Equivalent to Subutex or Suboxone Sublingual Tablets Containing ≤ 8 mg of Buprenorphine

| Drug | Transmucosal Formulation* | Brand/ | Brand/ Generic Strength | Subutex/Suboxone [‡] Sublingual Tablet Strength |
|------------------------------------|----------------------------|----------|---|--|
| | | | <i>Buprenorphine/Naloxone[§] Equivalency</i> | |
| buprenorphine HCL | Tablet, sublingual | Generic | 2 mg | 2 mg (Subutex) |
| | | | 8 mg | 8 mg (Subutex) |
| buprenorphine HCL/ naloxone HCL | Tablet, sublingual | Generic | 2 mg/0.5 mg | 2 mg/0.5 mg (Suboxone) |
| | | | 8 mg/2 mg | 8 mg/2 mg (Suboxone) |
| | | | Zubsolv | 1.4 mg/0.36 mg 2.9 mg/0.71 mg 5.7 mg/1.4 mg |
| | Film, buccal | Bunavail | 2.1 mg/0.3 mg | 4 mg/1 mg (Suboxone) |
| | | | 4.2 mg/0.7 mg | 8 mg/2 mg (Suboxone) |
| | Film, sublingual or buccal | Suboxone | 2 mg/0.5 mg | 2 mg/0.5 mg (Suboxone) |
| 4 mg/1 mg 8 mg/2 mg | | | 4 mg/1 mg (Suboxone) 8 mg/2 mg (Suboxone) | |

*Transmucosal formulations include buprenorphine and buprenorphine/naloxone sublingual tablets and buccal/sublingual films.

†For a more comprehensive listing of brand/generic sublingual/buccal transmucosal formulations see the U.S. Food & Drug Administration Orange Book: Approved drug products with therapeutic equivalence evaluations at http://www.accessdata.fda.gov/scripts/cder/ob/search_product.cfm.

‡Subutex (buprenorphine) and Suboxone (buprenorphine/naloxone) sublingual tablets, while used as buprenorphine equivalency references, are no longer available in the U.S.

§Naloxone (an opioid antagonist) is minimally absorbed in sublingual/buccal transmucosal formulations and rather is added to discourage diversion or misuse.

V. Dosage and Administration

| Drug Name | Dosing Regimen | Maximum Dose |
|---------------------------|--|--------------------------------------|
| Buprenorphine (Sublocade) | Two monthly initial doses of 300 mg subcutaneously followed by 100 mg monthly maintenance doses Increasing the maintenance to 300 mg monthly may be considered for patients in which the benefits outweigh the risks | 300 mg per month |
| Buprenorphine (Brixadi) | <u>Patients not currently receiving buprenorphine treatment</u> <ul style="list-style-type: none"> • The recommended weekly dose is 24 mg subcutaneously weekly titrated over the first week. If needed, during this week of treatment, administer an additional 8 mg | 32 mg per week or 128 mg per 28 days |

| Drug Name | Dosing Regimen | Maximum Dose |
|-----------|---|--------------|
| | <p>dose of Brixadi (weekly), waiting at least 24 hours after the previous injection, for a total weekly dose of 32 mg.</p> <ul style="list-style-type: none"> Administer subsequent weekly injections based on the total weekly dose that was established in week one. Dose adjustments can be made at weekly appointments with the maximum weekly dose being 32 mg. <p><u>Patients switching from transmucosal buprenorphine-containing products</u> Patients currently treated with a transmucosal buprenorphine-containing product may be switched directly to either weekly or monthly Brixadi. Refer to Prescribing Information for suggested corresponding weekly or monthly Brixadi.</p> <p><u>Patients transitioning between weekly and monthly Brixadi</u> Refer to Prescribing Information for recommended dose when transitioning between weekly and monthly Brixadi.</p> <p><u>Dose adjustments of Brixadi</u> An additional 8 mg of Brixadi (weekly) may be administered, based on clinical judgement during a dosing interval, up to a maximum dose of 32 mg per week or 128 mg per month.</p> <p><u>Other</u> Brixadi (weekly) should be administered in 7-day intervals. Brixadi (monthly) should be administered in 28-day intervals. Weekly doses of Brixadi cannot be combined to yield a monthly dose. Administer Brixadi as a single injection, and do not divide</p> | |

VI. Product Availability

| Drug Name | Availability |
|---------------------------|--|
| Buprenorphine (Sublocade) | Prefilled syringes: 100 mg/0.5 mL and 300 mg/1.5 mL |
| Buprenorphine (Brixadi) | <ul style="list-style-type: none"> Prefilled single-dose syringes – weekly: 8 mg/0.16 mL, 16 mg/0.32 mL, 24 mg/0.48 mL, and 32 mg/0.64 mL |

| Drug Name | Availability |
|-----------|---|
| | <ul style="list-style-type: none"> <li data-bbox="526 247 1354 310">Prefilled single-dose syringes – monthly: 64 mg/0.18 mL, 96 mg/0.27 mL, and 128 mg/0.36 mL |

VII. References

1. Sublocade Prescribing Information. North Chesterfield, VA: Indivior Inc.; September 2023. Available at <https://www.sublocade.com/>. Accessed October 19, 2023.
2. Brixadi Prescribing Information. Plymouth Meeting, PA: Braeburn Inc.; May 2023. Available at: <https://www.brixadi.com/>. Accessed October 19, 2023.
3. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.; 2018. Available at: <http://www.clinicalkey.com/pharmacology/>. Accessed November 14, 2023.
4. Center for Substance Abuse Treatment. Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction. Rockville (MD): Substance Abuse and Mental Health Services Administration (US); 2004. (Treatment Improvement Protocol (TIP) Series, No. 40.) Available from: <https://www.ncbi.nlm.nih.gov/books/NBK64245/>. Accessed November 14, 2023.
5. Center for Substance Abuse Treatment. Medications for opioid use disorder. Rockville (MD): Substance Abuse and Mental Health Services Administration (US); 2020. (Treatment Improvement Protocol (TIP) Series, No. 63) Available from: <https://store.samhsa.gov/product/TIP-63-Medications-for-Opioid-Use-Disorder-Full-Document/PEP20-02-01-006>. Accessed November 14, 2023.
6. Center for substance abuse treatment. Medication-assisted treatment for opioid addiction in opioid treatment programs. Treatment improvement protocol (TIP) series 43. DHHS Publication No. (SMA) 05-4048. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2005. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK64164/>. Accessed November 14, 2023.
7. Center for substance abuse treatment. Detoxification and substance abuse treatment. Treatment improvement protocol (TIP) Series, No. 45. HHS Publication No. (SMA) 15-4131. Rockville, MD: Center for Substance Abuse Treatment, 2006. Available at: <https://store.samhsa.gov/product/TIP-45-Detoxification-and-Substance-Abuse-Treatment/SMA15-4131>. Accessed November 14, 2023.
8. Kampman K and Jarvis M. American society of addiction medicine (ASAM): national practice guideline for the use of medications in the treatment of addiction involving opioid use. *J Addict Med.* 2015 Oct; 9(5):358-367. Available at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4605275/>. Accessed November 14, 2023.
9. Cunningham C, Edlund MJ, Gordon AJ et al. The ASAM national practice guideline for the treatment of opioid use disorder: 2020 focused update. Available from: <https://www.asam.org/quality-care/clinical-guidelines/national-practice-guideline>. Accessed November 14, 2023.

Coding Implications

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

| HCPCS Codes | Description |
|-------------|--|
| Q9991 | Injection, buprenorphine extended-release (Sublocade), less than or equal to 100 mg |
| Q9992 | Injection, buprenorphine extended-release (Sublocade), greater than 100 mg |
| J0577 | Injection, buprenorphine extended release (brixadi), less than or equal to 7 days of therapy |
| J0578 | Injection, buprenorphine extended release (brixadi), greater than 7 days of therapy |

| Reviews, Revisions, and Approvals | Date | P&T Approval Date |
|--|----------|-------------------|
| 1Q 2020 annual review: no significant changes; added HIM line of business; references reviewed and updated. | 11.26.19 | 02.20 |
| 1Q 2021 annual review: no significant changes; references to HIM.PHAR.21 revised to HIM.PA.154; added coding implications; references reviewed and updated. | 12.02.20 | 02.21 |
| Added separate approval duration for initial and continued approval of 12 months for HIM lines of business to meet regulatory requirements; added that approval durations should be 12 months for NH for other lines of business. | 11.02.21 | |
| 1Q 2022 annual review: no significant changes; references reviewed and updated. | 11.22.21 | 02.22 |
| In Section IIB clarified approval duration by removing references to implants which do not apply to Sublocade injection requests. | 06.09.22 | |
| Template changes applied to other diagnoses/indications and continued therapy section. | 09.20.22 | |
| 1Q 2023 annual review: no significant changes; removal of references to discontinued product Probuphine; references reviewed and updated. | 11.16.22 | 02.23 |
| 3Q 2023 annual review: for initial criteria, changed buprenorphine or buprenorphine-naloxone to buprenorphine-containing products and changed sublingual tablets or film to transmucosal buprenorphine; clarified oral buprenorphine as transmucosal buprenorphine; references reviewed and updated. RT4: Brixadi is now FDA approved – combined from previously approved pre-emptive policy CP.PHAR.498; clarified that at least one dose of oral buprenorphine means member should have tolerated a single 4 mg dose of or is currently being treated with a transmucosal-containing product. | 06.02.23 | 08.23 |
| Added HCPCS code [J0576] | 10.26.23 | |
| 1Q 2024 annual review: no significant changes; added HCPCS code [C9154] for Brixadi; references reviewed and updated. | 10.19.23 | 02.24 |
| Removed HCPCS codes [C9154, J0576] and added HCPCS codes [J0577, J0578] for Brixadi. | 02.22.24 | |

| Reviews, Revisions, and Approvals | Date | P&T Approval Date |
|--|----------|-------------------|
| Added disclaimer that medical management techniques, including quantity management, beyond step therapy is not allowed for members in NV per SB 439. | 05.30.24 | |

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions, and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment, or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members, and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members, and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

Note:

For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2016 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene[®] and Centene Corporation[®] are registered trademarks exclusively owned by Centene Corporation.